Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Supportive Care in Cancer
Published in: Supportive Care in Cancer 10/2009

01-10-2009 | Letter to the Editor

Transient secondary hyperparathyroidism following intravenous infusion of zoledronic acid

Authors: Stergios A. Polyzos, Athanasios D. Anastasilakis, Evangelos Terpos

Published in: Supportive Care in Cancer | Issue 10/2009

Login to get access

Excerpt

Dear Editor, …
Literature
1.
Sayin M, Yazici G (2009) Hyperparathyroidism secondary to zoledronic acid infusion: case report. Support Care Cancer 17:469–470PubMedCrossRef
2.
Avramidis A, Polyzos SA, Moralidis E et al (2008) Scintigraphic, biochemical, and clinical response to zoledronic acid treatment in patients with Paget's disease of bone. J Bone Miner Metab 26:635–641PubMedCrossRef
3.
Polyzos SA, Anastasilakis AD, Efstathiadou Z et al (2009) The effect of zoledronic acid on serum dickkopf-1, osteoprotegerin and RANKL in patients with Paget's disease of bone. Horm Metab Res 4. doi:10.​1016/​j.​bone.​2009.​03.​520
4.
Whitson HE, Lobaugh B, Lyles KW (2006) Severe hypocalcemia following bisphosphonate treatment in a patient with Paget's disease of bone. Bone 39:954–958PubMedCrossRef
5.
Cremers SC, Eekhoff ME, Den HJ, Hamdy NA, Vermeij P, Papapoulos SE (2003) Relationships between pharmacokinetics and rate of bone turnover after intravenous bisphosphonate (olpadronate) in patients with Paget's disease of bone. J Bone Miner Res 18:868–875PubMedCrossRef
6.
Polyzos SA, Anastasilakis AD, Terpos E (2009) Paget's disease of bone: a review with emphasis to treatment with zoledronic acid. Expert Rev Endocrinol Metab 4 (in press)
7.
8.
Nosaka K, Miyamoto T, Sakai T, Mitsuya H, Suda T, Matsuoka M (2002) Mechanism of hypercalcemia in adult T-cell leukemia: overexpression of receptor activator of nuclear factor kappaB ligand on adult T-cell leukemia cells. Blood 99:634–640PubMedCrossRef
9.
Gavriatopoulou M, Dimopoulos MA, Christoulas D et al (2009) Dickkopf-1: a suitable target for the management of myeloma bone disease. Expert Opin Ther Targets 13:839–848PubMedCrossRef
10.
Seymour JF, Gagel RF (1993) Calcitriol: the major humoral mediator of hypercalcemia in Hodgkin's disease and non-Hodgkin's lymphomas. Blood 82:1383–1394PubMed
Metadata
Title
Transient secondary hyperparathyroidism following intravenous infusion of zoledronic acid
Authors
Stergios A. Polyzos
Athanasios D. Anastasilakis
Evangelos Terpos
Publication date
01-10-2009
Publisher
Springer-Verlag
Published in
Supportive Care in Cancer / Issue 10/2009
Print ISSN: 0941-4355
Electronic ISSN: 1433-7339
DOI
https://doi.org/10.1007/s00520-009-0704-5

Other articles of this Issue 10/2009

Supportive Care in Cancer 10/2009 Go to the issue

Original Article

‘Quite an awkward situation to be in’: perceptions of patients, carers and health and social care professionals of the supportive cancer care in British military personnel stationed in Germany

Review Article

Quality of life in survivors of childhood cancer: a systematic review of the literature (2001–2008)

Original Article

Yoga of Awareness program for menopausal symptoms in breast cancer survivors: results from a randomized trial

Original Article

A longitudinal study of the role of patient-reported outcomes on survival prediction of palliative cancer inpatients in Taiwan

Original Article

Retrospective evaluation of weekly paclitaxel hypersensitivity reactions reported utilizing an electronic medical record system at a tertiary cancer center

Short Communication

Strength of skeletal muscle and quality of life in patients suffering from “typical male” carcinomas
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits